Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JMS CoTSE:7702 +0.44%60 Cash Ratio is 0.29 as of Mar. 2026, which is 3% below its 10-year median of 0.30. GuruFocus rates TSE:7702 with a GF Score™ of 60/100 and a GF Value™ of 円509.07 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 834 Medical Devices & Instruments companies, JMS Co ranks worse than 74.1% on this metric.
JMS Co has a Cash Ratio of 0.29. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for JMS Co's Cash Ratio or its related term are showing as below:
TSE:7702'
s Cash Ratio Range Over the Past 10 Years
Min: 0.22 Med: 0.3 Max: 0.34
Current: 0.33
During the past 13 years, JMS Co's highest Cash Ratio was 0.34. The lowest was 0.22. And the median was 0.30.
TSE:7702's Cash Ratio is ranked worse than 74.1% of 834
companies
in the Medical Devices & Instruments industry
Industry Median: 0.945
vs TSE:7702: 0.33
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
JMS Co Cash Ratio Related Terms
JMS Co Cash Ratio Historical Data
* Premium members only.
The historical data trend for JMS Co's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, JMS Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JMS Co Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, JMS Co's Cash Ratio distribution charts can be found below:
* The bar in red indicates where JMS Co's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JMS Co (TSE:7702) has a Cash Ratio of 0.29 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on JMS Co and its competitors. This is near median its historical median of 0.30. Over the past decade, JMS Co's Cash Ratio has ranged from 0.22 to 0.34. According to the industry distribution chart, JMS Co ranks #618 out of 834 companies in the Medical Devices & Instruments industry, placing it in the top 74.1%.
Is JMS Co's Cash Ratio too high?
JMS Co's current Cash Ratio of 0.29 is near median its 10-year median of 0.30. Over the past 10 years, this metric has ranged from a low of 0.22 to a high of 0.34. The Medical Devices & Instruments industry median Cash Ratio is 0.95. JMS Co's value of 0.29 is 69.3% below this industry median. Based on the distribution chart, JMS Co ranks #618 out of 834 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, JMS Co has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JMS Co's Cash Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, JMS Co ranks #618 out of 834 companies for Cash Ratio. This places JMS Co in the lower half of its industry. The industry median Cash Ratio is 0.95. JMS Co's value of 0.29 is 69.3% below this benchmark. Historically, JMS Co's own Cash Ratio has ranged from 0.22 to 0.34 over the past decade. While the company's 10-year median is 0.30 vs. the industry median of 0.95, JMS Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.95, based on 834 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JMS Co's current Cash Ratio of 0.29 is 69.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on JMS Co and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JMS Co's current Cash Ratio is 0.29, which is near median its own 10-year median of 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JMS Co stock overvalued right now?
Based on GuruFocus' analysis, JMS Co (TSE:7702) is currently considered Modestly Undervalued. The stock's GF Value™ is 円509.07, compared to a current price of 円453.00 — trading 11% below its estimated fair value. The current Cash Ratio is 0.29, which is near median its 10-year median of 0.30 and 69.3% below the Medical Devices & Instruments industry median of 0.95. JMS Co's overall GF Score™ is 60/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For JMS Co (TSE:7702), the current Cash Ratio is 0.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JMS Co (TSE:7702) Overvalued in 2026?
Based on GuruFocus' analysis, JMS Co stock appears to be undervalued.
The current stock price of 円453.00 is trading 11% below its estimated GF Value™ of 円509.07.
GuruFocus considers JMS Co to be Modestly Undervalued.
Key valuation signals for TSE:7702:
Cash Ratio: 0.29 (near median its 10-year median of 0.30)
GF Value™: 円509.07 vs. price of 円453.00 (11% below fair value)
Industry Position: 69.3% below the Medical Devices & Instruments median (#618 of 834)
No single metric tells the full story. See the TSE:7702 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JMS Co Ltd is a Japan-based medical equipment manufacturer. The company is engaged in the manufacture, sale, export, and import of medical equipment and pharmaceuticals. Products offered by the company include an infusion pump, syringe pump, surgical gown, peritoneal dialysate, dialyzer, mask cap, sheet for treatment, pacemaker, heat exchanger, blood bag, among others. JMS has network operations in various countries including Europe, North America, Asia, the Middle East, Latin America and Africa.
60GF Score
Get the complete analysis for TSE:7702
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7702 has been successfully added to your 
